Scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have made one of the most important discoveries to date in the study and treatment of BRCA1-deficient ...

In vitro cell killing proficiency of autologous immune cells educated with allogenic multi-cancer tumor cell lysate. First-in-human study of ZGGS15, a dual specific antibody targeting LAG-3 and TIGIT, ...

For years, developing selective FGFE2/3 inhibitors has been hindered by the extreme structural similarity among FGFR family members, leading to toxicities and resistance with current therapies.

ADT-007, a first-in-class pan-RAS inhibitor, addresses complex RAS mutational landscape of human cancers March 27, 2025 ...

Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful ...

Checkpoint inhibitors are an anticancer drug that indirectly attacks tumors. They depend on infusions of antibodies to block proteins called immune checkpoints. Specifically, they target one of three ...

- Financing accelerates development of lead candidate AV078, a CNS-penetrant selective mTORC1 inhibitor, and will fund completion of its Phase 2 clinical trial - Round co-led by Luma Group and CTI ...